Bio-Rad Laboratories entering into a partnership with Oncocyte to develop a transplant assay represents a strategic move to enhance its product portfolio, which could be viewed favorably by investors. Such collaborations can lead to new revenue streams and strengthen the company's position in the biotech market, likely resulting in a positive short-term impact on its stock price.

The announcement of a significant partnership agreement typically leads to positive investor sentiment, as it suggests potential for future revenue growth and market expansion. Given the specific nature of the partnership with Bio-Rad Laboratories, a well-regarded entity in the biotech field, Oncocyte's stock is likely to see a short-term uplift as investors react to the news.